
FDA accepts submission for selumetinib as treatment for neurofibromatosis
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, ...
Nov 14, 2019
0
4